Alzheimer's drug lecanemab shows reduced cognitive decline in clinical trial
A monoclonal antibody drug, named lecanemab, has been tested in a Phase III clinical trial in nearly 1800 participants, with promising results in reducing the effects of Alzheimer's disease on the brain.
Eisai (Tokyo, Japan) and Biogen (MA, USA) have released the results from their Phase III clinical trial of lecanemab, showing that the drug can slow cognitive decline in patients suffering with Alzheimer’s disease.
Lecanemab is an investigational anti-amyloid beta protofibril antibody that is used to treat mild cognitive impairment that occurs due to Alzheimer’s disease and early Alzheimer’s disease with amyloid pathology in the brain.
The trial, conducted over 18 months, was a multicentre, double-blind trial including 1795 patients from 50–90 years of age with early Alzheimer’s disease with amyloid.
The efficacy of the drug was based on end points of a change in score on the Clinical Dementia Rating–Sum of Boxes (CDR-SB) from baseline, and a change in amyloid burden as shown by positron-emission tomography (PET).
In the case of both end points, lecanemab appeared to reduce the amyloid burden in early Alzheimer’s disease and slowed decline in function and cognition according to the CDR-SB, compared to the placebo.
The results from the trial have been considered generally very positive, however, the researchers have stressed that application of lecanemab was associated with adverse events, and in 14% of the treatment group, severe adverse events. These reactions included infusion-related reactions, ARIA with microhaemorrhages, atrial fibrillation, syncope and angina. Deaths also occurred in 0.7% of the participants in the lecanemab group and 0.8% of the control group. The researchers highlight that the incidence of adverse events was similar between the test and control groups.
"All of these amyloid-lowering drugs carry a risk for increased brain haemorrhage," stated Ronald Petersen of the Mayo Clinic (MN, USA). "I think the primary outcomes, the secondary outcomes, the amyloid-lowering is pretty impressive."
The data presented in the paper, published in The New England Journal of Medicine, also showed that according to the CDR-SB, those who had a genetic disposition to developing early Alzheimer’s disease did not show significant improvements with lecanemab.
The companies have applied for accelerated approval for the drug from the US FDA, hoping to be able to conduct further long-term studies and start treating patients, stating that the earlier the drug can be used in the disease stage, the more impact it will have on slowing cognitive decline.
"I believe it's an important benefit that will justify full approval. But of course, we want a bigger benefit… before you've accumulated enough irreversible damage to be causing symptoms" commented Paul Aisen, Director of the University of Southern California Alzheimer’s Therapeutic Research Institute (CA, USA) and a co-author of the study.
Related News
-
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News Roche breaks into the obesity drug market with the acquisition of Carmot Therapeutics
In a bid to diversify their therapeutic offerings, Roche takes over Carmot Therapeutics in $2.7 billion deal, with one obesity drug spearheading the venture into the field as they prep for a Phase II in-human trial. -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News Women in Pharma: Delivering solutions for gender diversity
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona Speaker Interview – What the US FDA’s Quality Management Maturity Means for the Pharma Industry
At CPHI Barcelona (24–26 October, 2023), we spoke to Sireesha Yadlapalli, CEO of Pharmatech Associates, who gave a presentation on the implications of the US FDA’s Quality Management Maturity (QMM) Initiative, and spoke on the panel of the ... -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Wegovy and weight-loss drugs driving demand for manufacturers that can fill syringes
Injectable weight-loss treatments are prompting contract manufacturers to invest and include fill-finish services into their service portfolios, in a bid to attract pharmaceutical giants developing drugs similar to Novo Nordisk's Wegovy.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance